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Abstract
Each year on the 25th April Africa and the rest of the world commemorate Africa Malaria Day as
was agreed upon at the African Summit on Roll Back Malaria held in Abuja, Nigeria on 25th April
2000. The summit also called upon the United Nations to declare the period 2001–2010 a decade
for malaria. The 1st Africa Malaria Day was commemorated with the theme "Communities Play a
Central Role in Tackling Malaria". The 6th Africa Malaria Day was observed in 2006 with the theme
"Get Your ACT Together" and the slogan "Universal Access to Effective Malaria Treatment is a
Human Right". This article by the Secretariat of the Multilateral Initiative on Malaria (MIM) was also
part of the commemorations for the day. MIM was founded in 1997 as an alliance of institutions
and individuals concerned with the malaria problem, and aiming at maximizing the impact of
scientific research on malaria through strengthening African research capacity and coordinated
global collaboration. The MIM Secretariat has been hosted in rotation by the founding institutions,
and is being hosted for the first time in Africa by the African Malaria Network Trust (AMANET) in
Dar es Salaam, Tanzania. This article reviews the malaria situation in Africa six years after the Abuja
Declaration, highlighting the disease burden trends, failures, achievements, challenges, and the way
forward.
Background
Malaria is a preventable disease that afflicts hundreds of
millions of people causing among them untoward socio-
economic suffering including a vicious circle of abject
poverty, brain damage, other irreversible disabilities, and
over one million deaths per year. Notwithstanding this
leading disease burden, malaria has yet to get the status it
deserves on the political and other relevant agenda of
endemic communities and development partners. The
historic Abuja Declaration on Malaria promulgated by the
Summit on Malaria in Abuja, Nigeria on 25th April 2000,
like many other preceding ones, remains mostly on the
drawing board as demonstrated by available statistics [1].
As Africa and the rest of the World commemorate the
Africa Malaria Day on 25 April 2006 it should be noted
among other observations that there is yet much to be
done in sub-Sahara Africa where malaria exalts the great-
est toll. No more than 60% of those suffering from
malaria have prompt access to and are able to use correct,
affordable and appropriate treatment within 24 hours of
onset of symptoms [2]. Only 60% of the most vulnerable
populations of pregnant women and children under-five
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years of age is estimated to benefit from the most effective
combination of personal and community protective
measures such as insecticide treated nets and other inter-
ventions. For example, it is estimated that of all pregnant
women, only 60% has access to chemoprophylaxis by pre-
sumptive intermittent treatment as Africa Malaria Day is
being commemorated for the sixth time since 2001. This
article explores the current situation and what is being
done to address the malaria problem.
Malaria as a public health crisis
In Africa the annual economic burden of malaria has been
estimated to be about US $12 billion, and to slow eco-
nomic growth by about 1.3%. Besides contributing to loss
of life, malaria morbidity may cause anaemia and its var-
ious complications, miscarriage, brain damage, decreased
cognition, and productivity. It hampers children's educa-
tion and social development through sickness absentee-
ism and neurological disabilities caused by severe
infections. Adults debilitated by the disease either cannot
work or do so at decreased capacity, and therefore lose
earnings. Furthermore, the education system becomes dis-
rupted when children are either too sick to attend school,
or their teachers are absent because of malaria-related ill-
nesses [3,4].
The malaria toll is staggering for every 40 seconds a child
dies of malaria, resulting in a daily loss of more than
2,000 young lives worldwide. It is the leading cause of
mortality and morbidity worldwide being estimated to
cause 300 to 500 million clinical cases every year and
between one and three million deaths, mostly among
children [4]. Ninety per cent of those who die of malaria
are in Africa, where the disease accounts for about one in
five of all childhood deaths. Children who survive severe
malaria may develop brain damage and become cogni-
tively disabled. Malaria infections may also interact with
other afflictions such as HIV infection, and under-nutri-
tion, in ways that are still not well understood.
Malaria historical perspectives
Some circumstantial evidences based on people move-
ments suggest that man and malaria have evolved
together, and that most, of today's populations of human
malaria parasite species may have had their origin in West
Africa. Hippocrates was the first to describe malaria man-
ifestations and related them to the time of year and to
where the patients lived. Before this time the manifesta-
tions were blamed on supernatural powers. The associa-
tion with stagnant waters now known to be breeding sites
for Anopheles mosquito vectors, led the Romans to begin
drainage programmes, which was therefore the first inter-
vention against malaria. The name malaria, meaning bad
air, has its origins there.
The first recorded malaria treatment dates back to 1600,
when the bitter bark of the cinchona tree used by the
native Peruvian Indians to treat fevers, came to the atten-
tion of Europe through the Jesuits. The cinchona tree bark
extract has since provided quinine, which is now the treat-
ment of choice for severe malaria. Similarly, 2000 years
ago the Chinese developed a fever medicine from the
wormwood Artemisia annua from which artemisinins are
nowadays extracted for the Artemisinin Combination
Therapy (ACTs) being adopted as first line treatment for
malaria. The plant has also become a new cash crop in
some parts of East Africa.
The aetiological agent of malaria was in 1889 elicited to
be a protozoa by Laveran while working in Algeria, and
the Anopheles mosquito was demonstrated in 1897 to be
the vector for the protozoa. At this point the major fea-
tures of the epidemiology of malaria seemed clear, and
control measures started to be implemented. In East Africa
for example, during the early 1900s European colonizers
took quinine regularly as preventive treatment. At the
same time they started controlling mosquito breeding in
towns where they mainly lived, mines, and farms supply-
ing goods to European industries [5].
The Second World War (WW II) was a boon to the malaria
control efforts by bringing the warring powers into the
tropics where malaria was rife. It was, therefore, essential
to discover, develop and deploy new malaria control tools
in order to protect the forces exposed to malaria and other
tropical diseases. So it was part of the war effort that led to
the introduction of such new malaria control products as
Dichloro-diphenyl-trichloroethane (DDT) and related
insecticidal chemicals. Chloroquine and its relative drugs,
which later constituted the mainstay of malaria preven-
tion and control were also part of the war efforts to pro-
vide malaria interventions. Even sulphadoxine-
pyrimethamine (SP) was developed in order to contain
chloroquine resistant malaria during the Vietnam War.
After the WWII both DDT and chloroquine entered civil-
ian use. Since these interventions were so efficacious and
effective they were adopted for use in community wide
malaria control programmes. By the 1950s there was so
much confidence in the prowess of these tools, that an all
out war to eradicate malaria from the entire world was
declared mainly relying on DDT and chloroquine.
What went wrong?
Despite initial malaria eradication success in Europe and
North America, elsewhere success was mixed. In Latin
America and many parts of Asia, there were control suc-
cesses rather than eradication of the disease, as were in
only a few African areas in the southern fringes, high alti-
tude areas, and islands far from the continent. However,
in many parts of Africa particularly in the savannas,Malaria Journal 2006, 5:102 http://www.malariajournal.com/content/5/1/102
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malaria control success was really very limited. As a result,
and taking into account the historical tumultuous changes
of the early 1960s, malaria eradication in Africa was
totally abandoned. The countries in Asia and Latin Amer-
ica were implementation of the interventions was sus-
tained, show very obvious differences between their
malaria picture versus that in Africa.
Recently African countries that have reverted to DDT use
have seen spectacular successes in their malaria control
efforts. These include South Africa, Mozambique, Zambia,
Madagascar and Swaziland who within two years of start-
ing DDT programmes, slashed their malaria rates by 75
percent or more. With fewer people getting sick, access to
ACT drugs should be more feasible to nearly all victims,
which should also cut malaria rates even further. Other
African countries should learn from these shining exam-
ples, and start using DDT instead of sitting on the fence
appeasing environmentalists who appear to care less
about the lives of others.
Why the failure?
Malaria is a classic of the neglected diseases, characterized
by a high disease burden in the developing world, a low
disease burden in high-income nations, and a low level of
funding in relation to the disease burden. As with other
neglected diseases, the perceived lack of a lucrative con-
sumer market for antimalarial products explains the rela-
tively low rate of research and development (R&D)
investment by the private sector. This situation has there-
fore necessitated government support to be the corner-
stone of malaria R&D funding [6].
As stated earlier, many of the best antimalarial medicines
benefited from war research efforts and investments. Not
infrequently such investments ceased during years of
peace. The development of insecticidal chemicals enjoyed
great investments not only during the war years, but also
during peace. Indeed much of this investment was ini-
tially meant for agricultural purposes. Quite often chemi-
cals that were successfully used in agriculture were later
tried for public health use before introducing the success-
ful ones for community wide disease control.
The pyrethroids used today on the insecticide treated nets
(ITNs) illustrate the point well. They were introduced in
agriculture during the 1970s. In the following decade
(1980s) trials of ITNs started, and by the mid 1980s scien-
tists working in Gambia and Tanzania published papers
demonstrating their efficacy in mosquito control. By the
early 1990s there were already publications confirming
their protection of human beings against malaria. Unfor-
tunately, it is only now, close to three decades after the
introduction of pyrethroids in agriculture, that attempts
are being made to scale up the use of ITNs for real public
health impact.
Furthermore, the impact of these insecticides cannot be
expected to last for ever; indeed there is already good sci-
entific evidence predicting their future failure. When they
fail, if the global insecticidal arsenal has not changed,
there will be no fall back position. As the chemical indus-
try is least interested in developing protective products for
the poor, and governments, particularly of malaria
endemic countries which need the alternative are more or
less incapacitated, there might be real grave danger when
pyrethroid resistance increases to the point of affecting
control programmes. The only hope on the horizon is the
Bill and Melinda Gates Foundation, which recently pro-
vided a grant to the Liverpool School of Tropical Medicine
to develop a completely new class of safe insecticides to
provide a fall back position.
Malaria resurgence
Continental sub-Saharan Africa was never a part of the
global malaria eradication programme. The severity of the
disease, density and efficiency of Anopheles gambiae mos-
quito vectors, feasibility of eradicating the disease over
such a large land mass with recurrent reinvasions, high
costs, and subsequent maintenance, must have all con-
tributed to the lack of will to undertake a continental erad-
ication programme. Also, the eradication programme
period coincided with the colonial and immediate postco-
lonial periods, during which little or no indigenous capac-
ity was available to initiate and sustain malaria
eradication. After a period of laissez faire regarding
malaria control, these countries have had to face the re-
emergence of the disease.
In recent years, reported malaria cases have been rising
especially in sub-Saharan Africa. This rise could be attrib-
uted to the improved coverage of Health Information Sys-
tems (HIS), and misdiagnosis due to the general rise in
fevers associated with other diseases like HIV/AIDS. How-
ever, for countries with more robust data the rise in
malaria cases remains strong suggesting that the scale of
the malaria problem is escalating. Some of the often men-
tioned reasons for this resurgence include among others;
deteriorating health sectors within the region, a break-
down in malaria control efforts, rising drug and insecti-
cide resistance, population movements, and
environmental changes favouring increased malaria trans-
mission [7]. The rises in drug and insecticide resistance
deserve special mention. It is known today that malaria
resistance to drugs started in East Africa during the late
1970s. Eventually chloroquine was completely lost in the
late 1990s, so the change from chloroquine to other drugs
happened during the early years of this millennium. This
delayed decision surely caused many unnecessary deaths.Malaria Journal 2006, 5:102 http://www.malariajournal.com/content/5/1/102
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Already there is a mounting wave of SP resistance [8].
Surely Africa and the rest of the world community cannot
afford more disastrous delays in policy changes. Admit-
tedly, there are many important questions begging for
answers including whether there is enough knowledge
about the disease and its determinants, enough tools, ade-
quate resources, and whether governments and popula-
tions of disease-endemic countries are adequately
prepared? Much as important as these questions are, they
do not warrant a neglect on investing sufficiently in the
fight against malaria as Africa's leading public health
enemy.
Success stories
Amid the malaria deaths and sufferings, progress is being
made. African countries in 2000 committed themselves to
providing by the end of 2005 prompt and effective treat-
ment and insecticide-treated nets (ITNs) for 60% of the
people at highest risk of malaria and intermittent preven-
tive treatment (IPT) for 60% of pregnant women. Initially,
implementation of these measures was severely limited by
a shortage of resources for procurement of commodities.
But the situation in some countries is improving. Some
countries have reached or exceeded at least some of these
targets with recent increases in funding from new sources.
Most of the remaining countries are now poised to begin
scaling up, although substantial challenges remain.
With respect to prompt and effective treatment, surveys
have shown that on average half of African children with
fever are treated with an antimalarial drug. Unfortunately,
most of these treatments still involve chloroquine to
which the parasite Plasmodium falciparum show very high
resistance rates. Increasing both availability and accessi-
bility to ACTs constituting the new and highly effective
treatment against falciparum malaria, are expected to
improve treatment outcomes within the next few years. By
the end of 2004 about 23 African countries had changed
their national drug policy and adopted ACTs.
With respect to progress on prevention, the number of
ITNs distributed during the past 3 years has increased 10-
fold in more than 14 African countries. Subsidized or free-
of-charge ITN distribution has proved successful in
increasing coverage of the most vulnerable populations.
In most African countries, many more households have
mosquito nets not treated with insecticide than ITNs. Scal-
ing up of insecticide re-treatment services will, therefore,
also be an important factor in increasing ITN coverage.
The recent introduction and manufacture of permanently
treated nets is expected to greatly improve overall efficacy
and effectiveness.
Efforts to prevent the silent but significant burden of
asymptomatic infections in pregnant women residing in
areas of stable malaria transmission have been revitalized
through partnerships between malaria and reproductive
health programmes. A total of 11 African countries, in
addition to scaling up delivery of ITNs to pregnant
women, are now in the process of implementing intermit-
tent preventive treatment (IPT) for pregnant women [9].
New techniques against an old scourge
Over the last three decades there has been considerable
interest in research and development of malaria vaccines.
Research results that have been obtained so far show that
malaria vaccine candidates would differ not only in their
biological properties, but also in their eventual applica-
tions. Pre-erythrocytic stage vaccines also called sporo-
zoite vaccines would generally prevent malaria infections.
Asexual stage malaria vaccine candidates also called blood
stage vaccines would prevent development of the disease.
Sexual stage (gametocytes) malaria vaccine candidates
also referred to as transmission blocking vaccines would
block malaria transmission.
There is clearly a need to take advantage of ongoing
advances in scientific research especially in biotechnology
and related endeavours to develop the badly needed
malaria vaccines. In order to sustain such efforts and
ensure their eventual deployment in malarious communi-
ties it is absolutely essential that African researchers partic-
ipate fully in the creation of the new products so as to
ensure their progress in the entire product development
pipeline. However, examination of the malaria vaccine
development process reveals that all malaria vaccine dis-
coveries, patenting, pre-clinical testing, are undertaken in
well endowed northern institutions. Similarly, the current
Good Manufacturing Practice (c-GMP) manufacture of
test products is restricted to the north. Even early phase
malaria vaccine testing is carried out in the north. Only
products that are safe in very preliminary testing are tested
in African populations.
Capacity building
Achieving victory over malaria in Africa requires a new
internationally funded effort dedicated to training and
supporting a critical mass of African malaria researchers
for their parallel involvement with researchers in the
North for successful implementation of new research
findings for reversing the situation in malaria endemic
countries. Although there are several dozen malaria
research institutions in Africa only a handful of those with
strong historical links to northern institutions are ever
involved in the testing of malaria vaccine candidates.
Institutions lacking such links, most of which are African
owned by ministries of science and technology, or minis-
tries of health, or universities may be better placed to
translate new knowledge from research into effective
intervention tools. However, these are often short ofMalaria Journal 2006, 5:102 http://www.malariajournal.com/content/5/1/102
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essential personnel, equipment, infrastructure, and are
therefore avoided in product development. The need to
strengthen these neglected sites is obvious.
Malaria R & D
For too long the global community has been reluctant to
invest sufficient resources in fighting malaria, leaving it
near the bottom of the world's health agenda. However,
with the recent gradual increase in international aware-
ness of the problem, malaria is now on the agenda of the
health community, political arena, and international
financial institutions.
In 1997, the Multilateral Initiative on Malaria (MIM), an
alliance of agencies, institutions, and governments, was
formed to maximize the impact of scientific research on
malaria through capacity building in Africa and global
collaboration. The following year, the World Health
Organization (WHO), United Nations Children's Fund
(UNICEF), United Nations Development Program
(UNDP), and the World Bank, launched the Roll Back
Malaria (RBM) Global Partnership to coordinate efforts in
fighting malaria. RBM today involves 90 countries, com-
panies, and other organizations. It recently published its
"World Malaria Report 2005" on progress toward its goal
of halving the burden of malaria by 2010.
Multilateral Initiative on Malaria (MIM)
MIM is a global alliance of organizations and individuals,
funding partners, and four autonomous constituents
comprising the MIM Secretariat, MIM and the Special Pro-
gramme for Research and Training in Tropical Diseases
(MIM/TDR, MIM Communication Network (MIMCom),
and Malaria Research and Reference Reagent Resource
Center (MR4). The MIM mission is to maximize the
impact of scientific research on malaria in Africa, through
research capacity building and global collaboration, and
coordination [10]. The MIM alliance is playing a critical
role in the emergence of a growing body of reference
research institutions staffed by well-trained national sci-
entists and working well-rounded teams and partner-
ships. Most of the scientists supported by MIM ever since
its inception are now holding key posts in academia,
health ministries, and international organizations, where
they are helping shape national and international malaria
agendas and also facilitating improved and effective
malaria control in Africa.
MIM is also contributing to sustainable research capacity
in Africa in other various ways by providing through MIM-
Com mechanisms for communication and information
sharing, MIM/TDR opportunities for collaborative/multi-
center research, MR4 access to well-defined, standardized
reagents, MIM Secretariat dissemination of information
regarding research opportunities and findings through the
MIM Pan-African Malaria Conferences.
International donors recently pledged $3.7 billion to The
Global Fund for AIDS, Tuberculosis and Malaria
(GFATM) for 2006 and 2007. The amount represents
about half of the $7 billion it says it will need to fund all
of its programmes for the two-year period. GFATM pro-
vides nearly three-quarters of all the money spent on
malaria control including procurement of drugs and
ITNs,, and has committed about $1 billion toward that
end over the next two years. In 2004, it switched its sup-
port from general antimalarials to the purchase of ACTs
by governments receiving its grants. Over the next two
years, GFATM is expected to provide about 145 million
ACT treatments [11]. Since GFATM began disbursing
funds in 2003, the demand for combination therapies
based on artemisinin has increased rapidly and led to a
drug shortage in late 2004. In order to ensure the quality
of the drugs, WHO and the United Nations Children's
Fund (UNICEF) have established a mechanism to pre-
qualify manufacturers, and are calling on countries to use
only WHO-approved ACTs.
The G8 got behind an £800 m fund to battle malaria; the
Bill and Melinda Gates Foundation announced still more
money to hunt down a vaccine against this disease. Many
other philanthropic organization and institutions have
emerged to lend hands in the battle against malaria. Such
august institutions include GlaxoSmithKline (GSK), Well-
come Trust, Fogarty International Center (FIC) of the of
the US National Institutes of Health (NIH), London
School of Hygiene and Tropical Medicine (LSHTM), Afri-
can Malaria Network Trust (AMANET), Multilateral Initi-
ative on Malaria (MIM), Malaria Vaccine Initiative (MVI),
European Malaria Vaccine Initiative (EMVI) and the list
continues.
What is the way forward?
Malaria is an important social, economic, and develop-
mental problem affecting individuals, families, commu-
nities, and countries. The best chance for successfully
combating the disease requires collaboration not only of
those responsible for control and research but also many
other sectors, including for example agriculture, industry
and commerce, transport, judiciary, education, youth,
gender, children, and of course finance and planning. The
research crucially important south-south, south-north,
and north-north collaborations, are being promoted by
MIM.
Among the ideas being nourished regarding research
training is the initiative that would focus on competitively
awarded long-term grants that would be dedicated to
developing new "centres of research excellence" inPublish with BioMed Central    and   every 
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malaria endemic areas of Africa. These centres would serve
as hubs for training new scientists and assembling inter-
disciplinary teams for conducting major malaria research.
In addition, an African malaria research and control forum
will be established to translate malaria research results
into action, discussions on malaria control success stories,
research priorities, and advocacy for increased goodwill
and investments in malaria research and control.
The MIM Secretariat has been ably hosted by the Well-
come Trust (1997–1999), Fogarty International Centre
(FIC) of the US NIH (1999–2002) and lately by Stock-
holm University and Karolinska Institutet (2003–2005).
The African Malaria Network Trust (AMANET) whose mis-
sion is to promote capacity strengthening and networking
of malaria R&D in Africa is hosting the MIM Secretariat
from January 2006 to December 2010.
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